Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 146 peer-reviewed journal articles Updated
Oncology

Orienting Yourself After an HCC Diagnosis

At a Glance

Hepatocellular Carcinoma (HCC) is a primary liver cancer that often requires managing both the tumor and underlying liver health, such as cirrhosis. It can frequently be diagnosed without a biopsy using specialized scans, and early-stage treatment often involves surgery or liver transplantation.

Receiving a diagnosis of Hepatocellular Carcinoma (HCC) — the most common type of primary liver cancer — often feels like the world has suddenly shifted. It is completely normal to feel overwhelmed, scared, or even angry [1]. While this news is significant, the first step in regaining your footing is understanding exactly what is happening in your body and what the road ahead might look like.

Defining Your Diagnosis

In plain language, Hepatocellular Carcinoma is a cancer that begins in the hepatocytes, which are the main functional cells of your liver [2]. Unlike some other cancers that can spread to the liver from elsewhere, HCC starts in the liver itself [1].

Doctors often view HCC as a “two-disease” condition [1][3]. This is because the cancer almost always develops in a liver that has already been under stress from chronic inflammation or scarring, known as cirrhosis [1][4]. Because of this, your care team will be looking at two things simultaneously:

  1. The Cancer: The size, number, and location of the tumors.
  2. The Liver Health: How well the rest of your liver is still functioning [3][5].

Three Stabilizing Facts

When the “panic spiral” starts, it can help to ground yourself in these three research-backed facts:

  • You Have a Standardized Roadmap: Doctors use a highly specific, international system called LI-RADS to diagnose and stage HCC [6][7]. This means your diagnosis isn’t a “guess” — it is based on a rigorous, math-like framework that ensures you receive the most accurate assessment possible [8][9].
  • Surgery is Often a First-Line Option: For many patients with localized tumors, surgical resection (removing the tumor) remains a durable and effective first-line treatment [10][11]. If surgery isn’t the right fit, liver transplantation is often considered a “curative” option that treats both the cancer and the underlying liver disease [12][13].
  • Your Care is a Team Effort: Because HCC is complex, modern medicine uses a multidisciplinary approach [2][14]. This means you aren’t just relying on one doctor; instead, experts in liver health (hepatologists), cancer (oncologists), and surgery work together to build a plan tailored to your specific liver function and tumor profile [2][15].

Understanding the Path Ahead

While every patient’s journey is unique, the typical course involves several key milestones that research and clinical guidelines agree upon:

What Research Agrees On:

  • Non-Invasive Diagnosis: In many cases, HCC can be diagnosed with high certainty using specialized CT or MRI scans without needing a needle biopsy [6][7].
  • The Milan Criteria: This is a set of “gold standard” measurements (usually one tumor ≤5\le 5 cm or up to three tumors ≤3\le 3 cm each) that help doctors determine if a patient is an ideal candidate for a liver transplant [16][17].

Common Misunderstandings:

  • Misunderstanding: “A liver cancer diagnosis means the liver has completely failed.”
  • Fact: Many people are diagnosed while their liver function is still “preserved,” meaning the liver is still doing its job well enough to handle various treatments [12][18].
  • Misunderstanding: “I must have done something wrong to get this.”
  • Fact: HCC is often the result of long-term inflammation from many sources, including viral hepatitis or metabolic factors that may have been present for decades without symptoms [2][19].

Where Uncertainty Remains:
While doctors have excellent tools for diagnosis, predicting exactly how a specific tumor will respond to newer “systemic” therapies (like immunotherapy) is still an active area of research [20][21]. Your team will monitor you closely to adjust your treatment plan based on how your body responds [22].

Navigating This Guide

This resource is designed to walk you through every step of the process. Below, you will find links to detailed pages covering everything from the biology of HCC to post-treatment surveillance:

01

The Biology of How HCC Develops

Learn how Hepatocellular Carcinoma (HCC) develops over time. Understand the viral and metabolic paths to liver cancer, chronic inflammation, and DNA damage.

02

Decoding Your Scans: How HCC is Diagnosed Without a Biopsy

Learn how hepatocellular carcinoma (HCC) is diagnosed without a biopsy. Understand LI-RADS scores, Eovist MRI scans, washout, and AFP blood test results.

03

How Doctors Determine Your Stage and Liver Health

Learn how doctors stage hepatocellular carcinoma (HCC) by assessing both the tumor and your liver health using BCLC, Child-Pugh, and ALBI scoring systems.

04

Treating Early and Intermediate HCC: Surgery and Localized Options

Discover treatment options for early and intermediate HCC. Learn how surgical resection, liver transplants, ablation, TACE, and TARE target liver tumors.

05

Advanced HCC: Understanding Systemic and Immunotherapies

Learn about systemic and immunotherapy options for advanced HCC (liver cancer). Understand treatments like Atezo/Bev, the STRIDE regimen, and Lenvatinib.

06

Life After Treatment: Surveillance and Your Long-Term Health

Learn what to expect after HCC liver cancer treatment. Understand your surveillance schedule, MRI scans, AFP tests, recurrence risks, and managing scanxiety.

Common questions in this guide

What is the difference between hepatocellular carcinoma and other liver cancers?
Hepatocellular carcinoma starts directly in the hepatocytes, which are the main functioning cells of your liver. This makes it a primary liver cancer, unlike secondary cancers that start elsewhere in the body and spread to the liver later.
Why do doctors call HCC a two-disease condition?
HCC almost always develops in a liver that has already been under stress from chronic inflammation or scarring, known as cirrhosis. Because of this, your care team must simultaneously treat the cancer and manage the overall health of your liver.
Do I need a biopsy to be diagnosed with HCC?
Often, a biopsy is not needed. Doctors can frequently diagnose HCC with high certainty using specialized CT or MRI scans that follow a rigorous, standardized scoring system called LI-RADS.
What are the first-line treatments for localized HCC?
For many patients with localized tumors, surgically removing the tumor is a highly effective first-line option. If surgical resection isn't the right fit, a liver transplant may be considered to treat both the cancer and the underlying liver disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific diagnosis, which of these pages should I focus on first?
  2. 2.How does the information in this guide apply to my specific BCLC stage and liver function?
  3. 3.Who on my care team is the best person to contact if I have questions about the material here?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.

    Borgia M, Dal Bo M, Toffoli G

    Cancers 2021; (13(17)) doi:10.3390/cancers13174387.

    PMID: 34503196
  2. 2

    Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Benson AB, D'Angelica MI, Abbott DE, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(5)):541-565.

    PMID: 34030131
  3. 3

    Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.

    Orci LA, Sanduzzi-Zamparelli M, Caballol B, et al.

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022; (20(2)):283-292.e10 doi:10.1016/j.cgh.2021.05.002.

    PMID: 33965578
  4. 4

    The Role of Diagnosis and Treatment of Underlying Liver Disease for the Prognosis of Primary Liver Cancer.

    Shiani A, Narayanan S, Pena L, Friedman M

    Cancer control : journal of the Moffitt Cancer Center 2017; (24(3)):1073274817729240 doi:10.1177/1073274817729240.

    PMID: 28975833
  5. 5

    Hepatocellular Carcinoma Risk Scores from Modeling to Real Clinical Practice in Areas Highly Endemic for Hepatitis B Infection.

    Hao X, Fan R, Zeng HM, Hou JL

    Journal of clinical and translational hepatology 2023; (11(7)):1508-1519 doi:10.14218/JCTH.2023.00087.

    PMID: 38161501
  6. 6

    Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.

    Ren AH, Zhao PF, Yang DW, et al.

    Journal of magnetic resonance imaging : JMRI 2019; (50(3)):746-755 doi:10.1002/jmri.26640.

    PMID: 30648327
  7. 7

    Role of US LI-RADS in the LI-RADS Algorithm.

    Rodgers SK, Fetzer DT, Gabriel H, et al.

    Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(3)):690-708 doi:10.1148/rg.2019180158.

    PMID: 31059393
  8. 8

    Diagnostic Performance of LI-RADS Version 2018 for Primary Liver Cancer in Patients With Liver Cirrhosis on Enhanced MRI.

    Liu X, Ni X, Li Y, et al.

    Frontiers in oncology 2022; (12()):934045 doi:10.3389/fonc.2022.934045.

    PMID: 35847955
  9. 9

    CT and MRI Liver Imaging Reporting and Data System Version 2018 for Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.

    Lee S, Kim YY, Shin J, et al.

    Journal of the American College of Radiology : JACR 2020; (17(10)):1199-1206 doi:10.1016/j.jacr.2020.06.005.

    PMID: 32640250
  10. 10

    Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis.

    Hasjim BJ, Paukner M, Kwong AJ, et al.

    Transplantation 2026; (110(1)):e204-e216 doi:10.1097/TP.0000000000005536.

    PMID: 41082247
  11. 11

    Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis.

    Lee GC, Ferrone CR, Vagefi PA, et al.

    American journal of surgery 2019; (218(1)):157-163 doi:10.1016/j.amjsurg.2018.12.067.

    PMID: 30635211
  12. 12

    Liver transplant offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function.

    Benjamin AJ, Baker TB, Talamonti MS, et al.

    Surgery 2018; (163(3)):582-586 doi:10.1016/j.surg.2017.12.005.

    PMID: 29370929
  13. 13

    Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function.

    Liu JB, Baker TB, Suss NR, et al.

    Surgery 2017; (162(5)):1032-1039 doi:10.1016/j.surg.2017.07.017.

    PMID: 28866312
  14. 14

    Hepatocellular carcinoma: From diagnosis to treatment.

    Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, et al.

    Surgical oncology 2016; (25(2)):74-85.

    PMID: 27312032
  15. 15

    EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

    Journal of hepatology 2018; (69(1)):182-236 doi:10.1016/j.jhep.2018.03.019.

    PMID: 29628281
  16. 16

    Effect of MRI Versus MDCT on Milan Criteria Scores and Liver Transplantation Eligibility.

    Rostambeigi N, Taylor AJ, Golzarian J, et al.

    AJR. American journal of roentgenology 2016; (206(4)):726-33 doi:10.2214/AJR.15.14642.

    PMID: 26796867
  17. 17

    Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.

    Kim Y, Stahl CC, Makramalla A, et al.

    Surgery 2017; (162(6)):1250-1258 doi:10.1016/j.surg.2017.08.007.

    PMID: 29033224
  18. 18

    MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges.

    Phoolchund AGS, Khakoo SI

    Cancers 2024; (16(2)) doi:10.3390/cancers16020259.

    PMID: 38254750
  19. 19

    Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease.

    Suresh D, Srinivas AN, Kumar DP

    Frontiers in oncology 2020; (10()):601710 doi:10.3389/fonc.2020.601710.

    PMID: 33330100
  20. 20

    Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.

    Scarpellini E, Scarlata GGM, Santori V, et al.

    Biomedicines 2024; (12(8)) doi:10.3390/biomedicines12081797.

    PMID: 39200261
  21. 21

    Exosomes in hepatocellular carcinoma: a new horizon.

    Chen R, Xu X, Tao Y, et al.

    Cell communication and signaling : CCS 2019; (17(1)):1 doi:10.1186/s12964-018-0315-1.

    PMID: 30616541
  22. 22

    Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017.

    Seo N, Kim MS, Park MS, et al.

    European radiology 2020; (30(1)):261-271 doi:10.1007/s00330-019-06376-5.

    PMID: 31418085

This page provides an overview of hepatocellular carcinoma (HCC) for educational purposes. Always consult your oncology and hepatology care team for medical advice tailored to your specific diagnosis and liver function.

Get notified when new evidence is published on Hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.